|
Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on developing innovative therapies for unmet needs, announced two new partnerships aimed at enhancing the treatment experience for individuals living with attention-deficit/hyperactivity disorder (ADHD). Through collaborations with Calm Health and ADHD Central, Tris Pharma is extending support beyond prescription treatment by providing patients and their caregivers access to resources focused on mental wellness, organization, and day-to-day success.
As part of the initiative, eligible patients starting treatment with Dyanavel XR will receive three months of complimentary access to Calm Health, a clinical digital mental health platform and self-care app developed by psychologists. Calm Health delivers personalized action plans and evidence-based self-care programs designed to support emotional well-being and mental health. The platform includes ADHD-specific programmes that help patients build healthy habits, improve self-management skills, and better navigate the challenges associated with ADHD.
"Effective ADHD management often requires more than medication alone," said Manesh Naidu, chief commercial officer of Tris Pharma. "By partnering with Calm Health and ADHD Central, we hope to provide patients access to tools that may help support both their mental well-being and their daily organization. Our goal is to provide resources to people living with ADHD as they start a new treatment, and these partnerships reflect this commitment to meeting the full range of needs of the ADHD community."
In addition to the Calm Health partnership, Tris Pharma is proud to team up with ADHD Central. This company is dedicated to creating tactile, screen-free, and visual organization tools specifically designed for people with ADHD. Founded by Graham Meckling and Claire Butterfield, ADHD Central develops practical products that help individuals stay organized while reducing digital distractions. Among its offerings are the ON TRACK Cards, a visual task-management system designed to limit digital overwhelm and provide a clutter-free approach to managing daily responsibilities. Through this collaboration, Tris Pharma aims to introduce patients and caregivers to alternative strategies that support focus, productivity, and routine-building in everyday life.
The partnerships underscore Tris Pharma's broader mission to improve outcomes for people living with ADHD, including those who are sub-optimally managed, by expanding access to practical tools and resources that complement treatment and support long-term success. By increasing awareness of trusted mental health resources and practical organizational tools, Tris Pharma hopes to create a more holistic and supportive treatment experience for patients and families.
Dyanavel XR is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older.
The use of Dyanavel XR is not recommended in paediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
Dyanavel XR is a long-acting amphetamine-based treatment indicated for the management of ADHD. Designed to provide symptom control throughout the day, Dyanavel XR offers a treatment option for patients seeking individualized ADHD care.
Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris markets a portfolio of best-in-class ADHD products and is developing a promising pipeline of differentiated near-term drug candidates.
Calm Health is an evidence-based, configurable digital mental health solution from the makers of Calm, that helps individuals get the right support and stay engaged to improve health outcomes. Offered through employers, health plans and providers, Calm Health supports commercial, Medicare, Medicaid populations, and more.
ADHD Central is a small business creating screen-free, analog productivity tools designed specifically for ADHD brains. Founded by Graham Meckling and Claire Butterfield, the company builds tactile, paper-based products, including its flagship ON TRACK Cards, a pocket-sized daily planning system, that help people write things down, reduce digital overwhelm, and build habits that stick.
|